

ФАРМАКОЛОГИЯ, КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ
PHARMACOLOGY



DOI: 10.18413/2658-6533-2025-11-2-0-4

УДК 615

In-silico insights into α -Synuclein mediated pathology of Parkinson's disease using molecular docking and molecular dynamics simulation studies

Annu Grewal , Riddhi Sharma , Deepak Sheokand , Pawan Kumar ,
Vandana Saini , Ajit Kumar 

Maharshi Dayanand University,
Maharshi Dayanand University, Rohtak, 124001, India
Corresponding author: Ajit Kumar (akumar.cbt.mdu@gmail.com)

Abstract

Background: The precise cause of neuronal loss in Parkinson's disease (PD) is multifactorial, involving genetic and environmental factors. Genetic mutations, affecting many proteins such as α -Synuclein, Leucine-rich repeat kinase 2, and Parkin, have been implicated in sporadic and familial cases, shedding light on key molecular pathways involved in disease pathogenesis. **The aim of the study:** The present *in-silico* study was undertaken to study the hub protein responsible for PD pathogenesis and the effect of mutations on its pathophysiology. **Materials and methods:** Pathological proteins were selected using the KEGG database, and their protein-protein interaction mapping was done using the STRING database, followed by network merging and hub-protein identification using Cytoscape 3.9.1. Protein-protein docking studies were performed to study the pathology of identified hub-protein using Hex 8.00, and their validation was done by performing molecular dynamics simulation studies using GROMACS v2020.1. **Results:** α -Synuclein was identified as the hub protein responsible for PD pathology and studied for its pathological mechanism of aggregation in wild-type and mutated form (A53T, E46K, H50Q, A53E and G51D) using protein-protein docking studies. On decamerization, 4 of 5 studied SNPs (A53T, A53E, G51D and H50Q) showed better binding affinities in the VI-IV combination, while E46K showed better binding affinity in the VII-III combination than wild-type α -Synuclein. The SNPs – A53T, E46K and H50Q, demonstrated lower binding energies while 2 SNPs (A53E and G51D) displayed higher binding energies in decameric form than wild-type (WT) α -Synuclein aggregates. Also, G51D and E46K mutated oligomeric structures of α -Synuclein showed twisted morphologies. Molecular dynamics simulation studies provided evidence for the stabilized conformation of the decameric form of wild-type α -Synuclein. **Conclusion:** The study paves a good platform for further investigation to consider the decameric form of α -Synuclein protein as a target for PD therapeutics.

Keywords: Parkinson's disease; hub-protein; α -Synuclein; single nucleotide polymorphisms; aggregation; oligomerization; protein-protein docking; molecular dynamics simulation

Acknowledgements: the authors wish to thank UGC New Delhi for providing JRF to AG and the High-performance computing (HPC) facility ‘Param Smriti’, NABI, Mohali for the super-computational facility.

For citation: Grewal A, Sharma R, Sheokand D, et al. *In-silico* insights into α -Synuclein mediated pathology of Parkinson’s disease using molecular docking and molecular dynamics simulation studies. *Research Results in Biomedicine*. 2025;11(2):263-274. DOI:10.18413/2658-6533-2025-11-2-0-4

Introduction. Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the selective degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) of the brain [1]. The loss of dopaminergic neurons in the SNc leads to a decrease in dopamine levels in the striatum, thus playing a critical role in motor control and imbalances in the activity of striatal spiny projection neurons (SPNs) [2]. In the direct pathway of basal ganglia, the activity of striatal SPNs is reduced, leading to decreased facilitation of movement. Conversely, in the indirect pathway, the activity of striatal SPNs is increased, resulting in excessive inhibition of movement [3, 4]. These imbalances in the direct and indirect pathways contribute to the motor symptoms observed in PD, leading to bradykinesia, rigidity, and tremors.

The pathogenesis of PD involves a complex interplay between genetic and environmental factors. Genetic risk factors have been implicated in the development of sporadic and familial PD. Mutations in the SNCA gene, encoding the α -Synuclein protein, are found in familial forms of PD and are also associated with sporadic cases [5, 6]. Other genes associated with familial PD include Parkin [7], DJ-1 [8], PINK1 [9], and LRRK2 [10]. These genetic mutations disrupt various cellular processes within neurons and contribute to the neurodegenerative process in PD.

Understanding the underlying mechanisms of PD, the main protein targets, and the contributions of genetic mutations are crucial elements for the development of effective therapeutic strategies. Research efforts focused on elucidating these mechanisms are essential for identifying targets for disease-modifying interventions

and improving the therapeutic potentials of PD. The present study was carried out to identify the major therapeutic target protein(s) involved in the cause and progression of PD. Also, the study attempted to have *in-silico* insights into genetic variation(s), if any, of these target protein(s) and their role in PD.

Materials and Methods

Identification of target proteins and their protein-protein interactions

Different proteins/ protein-coding genes involved in the pathophysiology of Parkinson’s disease were identified using the KEGG pathway [11] database for diseases, with KEGG ID: map05012.

The protein-protein interaction (PPI) networks of these identified proteins/ protein-coding genes were retrieved using the STRING [12] database and a single merged protein-protein interaction network map was generated with a confidence score of 0.40, using Cytoscape 3.9.1 [13].

Hub-protein identification

The top 10 hub proteins involved in PD, were identified by selecting the “merged network” as the target network and the node score was calculated. The Maximal Clique Centrality (MCC) topological algorithm of the CytoHubba module [14] was used for Hub-proteins’ score calculation. The Analyzer tool of Cytoscape 3.9.1 was used to analyse the merged network.

Retrieval and energy optimization of the tertiary structure of identified hub-protein

The tertiary structure of the identified hub protein, involved in the pathophysiology of PD was retrieved from the RCSB Protein Data Bank (PDB) [15] and was subjected to energy minimization using UCSF Chimera [16] using default parameters, *i.e.*, 100 steps of

steepest descent (step size of 0.02 Angstrom) and 10 steps of the conjugate gradient algorithm (step size of 0.02 Angstrom), taking AMBERff14SB as the force field parameter, along with the addition of Gasteiger charges. The energy-minimized structure was saved in the PDB file format for further studies.

Text mining for genetic mutations in identified hub-protein and their structure modelling

An extensive literature search was performed to identify the non-synonymous SNPs/point mutations in the identified hub protein, reported to affect the pathophysiology of PD. The 3D structures of the mutated hub protein reported earlier were constructed by homology modelling using the Swiss Model [17]. The modelled structures were subjected to energy minimization and optimization using UCSF Chimera [16], using default parameters as mentioned in Section 2.3.

Protein-protein docking study

Protein-protein docking was carried out to study the role of mutations in Parkinson's disease, using Hex 8.0.0 with default parameters i.e. Correlation type – Shape + Electro; FFT Mode – 3D; Sampling method – Range angles; Grid dimension – 0.6; Solutions – 2000; Receptor range – 180; Step size – 7.5; Ligand range – 180; Step size – 7.5; Twist range – 360; Step size – 5.5; Distance range – 40; Box size – 10; Steric scan – 18; Final search – 25 [18].

Molecular dynamics simulation study

The stability of the protein-protein docked complex of the decameric form of the identified hub protein was analyzed by performing molecular dynamics simulation [MDS] using GROMACS v2020.1 [19]. The topology file of the protein was generated using charmm36m [20] force field. Solvation of the system was done by adding TIP3P water molecules followed by neutralization using Sodium (Na⁺) and Chloride (Cl⁻) ions at a concentration of 0.1M. For maximum stability, energy minimization of the system was performed using the steepest descent algorithm (5,000 steps) and potential energy of the system was lowered up to 1,000kJ/mol. Equilibration of the system was performed

under constant pressure (1 bar) and temperature (310K) conditions for 10ns using the Parrinello-Rahman barostat and Nose-Hoover thermostat, respectively. MDS was performed for 100ns using periodic boundary conditions and trajectories were recorded for every 100ps. Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), Radius of gyration (Rg) and Solvent Accessible Surface Area (SASA) were calculated for each frame during MDS analysis.

Results and discussion

Identification of target proteins and their protein-protein interaction study

A total of 7 protein-coding genes, majorly involved in the pathophysiology of PD, were identified using the direct and indirect pathways, as retrieved from the KEGG database. Both the pathways had 7 common target proteins i.e., α -Synuclein (SNCA), Parkin, Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1), Leucine-rich repeat kinase 2 (LRRK2), PTEN -induced kinase 1 (PINK1), Deglycase (DJ1) and High-temperature requirement A (HTRA2).

Retrieval of protein-protein interactions

The protein-protein interaction (PPI) networks of the identified target proteins were retrieved from the STRING database (Fig. 1a-g). These networks were analysed for the number of nodes, edges, and average local clustering coefficient. The PPI networks of all the studied proteins displayed 11 nodes (depicting proteins) with the number of edges (depicting protein-protein associations) varied from 24 to 43 while the average clustering coefficient was observed to be around 0.8 (Table 1). Edges displayed two types of interactions, known interactions which are either experimentally determined or retrieved from curated databases; and predicted interactions based on gene fusion, gene neighborhood, and gene co-occurrence. The merging of individual protein-protein interaction networks of all the studied proteins resulted in a single merged network map, which was used for identifying hub protein in the pathophysiology of PD.




Fig. 1. Protein-protein interaction network map of target proteins [a) Deglycase (DJ1); b) High-temperature requirement protein A2 (HTRA2); c) Leucine-rich repeat kinase 2 (LRRK2); d) Parkin; e) PTEN Induced kinase 1 (PINK1); f) α -Synuclein (SNCA) g) Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1)], as retrieved from STRING database. Coloured nodes displayed query proteins and the first shell of interactions, whereas white nodes displayed the second shell of interactions

Table 1

Protein-protein interaction network scores of respective genes obtained from the STRING database

S.No.	Name	Number of nodes	Number of edges	Average local clustering coefficient
1.	SNCA	11	34	0.835
2.	Parkin	11	39	0.835
3.	UCHL1	11	47	0.902
4.	LRRK2	11	24	0.813
5.	PINK1	11	43	0.818
6.	DJ1	11	35	0.827
7.	HTRA2	11	34	0.845

Hub-protein identification

The top 10 hub proteins were identified from the merged network map, based on the neighbourhood scores of nodes and edges using the MCC algorithm of the CytoHubba module (Table 2; Fig 2). The Analyzer tool provided the summary statistics of the undirected network map of the top 10 hub proteins (Table 2, 3) and the average number

of neighbors was observed to be 7.600 with a clustering coefficient of 0.927. α -Synuclein (SNCA) was identified as the top-ranked protein, having the highest MCC score of 12418, whereas UBC (Polyubiquitin-C) and UBB (Polyubiquitin-B) with respective MCC scores of 12408 and 11500, were identified as the second and third proteins of the top 3 scoring nodes.

Table 2

Ranking of top 10 Hub-proteins based on MCC scores obtained using CytoHubba

S. No.	Name	MCC Score	Rank
1.	SNCA	12418	1
2.	UBC	12408	2
3.	UBB	11520	3
4.	UBA52	11520	3
5.	RPS27A	11520	3
6.	UCHL1	11520	3
7.	HSPA8	10230	7
8.	TP53	5760	8
9.	LAMP2	5040	9
10.	PARK2	3438	10

Table 3

Network analyser summary statistics of the MCC top 10 merged network

S. No.	Parameter name	Value
1.	Number of nodes	10
2.	Number of edges	38
3.	Average number of neighbours	7.600
4.	Network diameter	2
5.	Network radius	1
6.	Characteristic path length	1.156
7.	Clustering coefficient	0.927
8.	Network density	0.844
9.	Network heterogeneity	0.222
10.	Network centralization	0.194
11.	Connected components	1




Fig. 2. Top scoring hub proteins identified using Maximal Clique Centrality (MCC) algorithm of Cytohubba (Red color signifies highest score, followed by orange and yellow)

α -Synuclein is known to exist in dynamic equilibrium between monomeric to oligomeric forms and vice-versa [21]. Monomeric α -Synuclein may combine to form a pathological conformer that follows a reversible pattern of aggregation, leading to the formation of oligomers, protofibrils and amyloid fibrils respectively. Multiple stacks of amyloid fibrils form irreversible circular disease-causing aggregations called Lewy bodies [22]. These aggregates are resistant to degradation due to the impaired ubiquitination system (UBB and UBC) [23]. α -Synuclein being the primary component of Lewy bodies, was selected for further studies of PD pathology.

Genetic mutations in identified hub-protein

Monomeric α -Synuclein (140 amino acids) has a differentially marked amphipathic amino-terminus (residue 1-60) – the site of single nucleotide polymorphisms (SNPs); hydrophobic non-amyloid- β component (NAC) domain (residue 61-95) – that forms the aggregation core; and acidic carboxy-terminal (residue 96-140) – the site of metal ion binding [21]. Various point-mutations or SNPs- A53T (dbSNP ID: rs104893877), A53E (dbSNP ID: rs1553408288), E46K (dbSNP ID: rs104893875), H50Q (dbSNP ID: rs201106962) and G51D (dbSNP ID: rs431905511), in the amphipathic region

of α -Synuclein, are reported to play possible roles in its rate of self-aggregation [24-27]. Hence, the role of these SNPs of α -Synuclein, on its self-aggregations, was analyzed using the *in-silico* tool of protein-protein docking.

Tertiary structure retrieval and optimisation of the identified hub-protein

The common kernel structure with preNAC and NAC regions of α -Synuclein (PDB ID: 6CU8), reported to show better self-association/aggregation properties [28], was selected for our study of self-aggregation rate and patterns of mutated α -Synuclein. The selected conformation had 10 chains of α -synuclein, so all chains except chain-A, were deleted and its energy-minimized structure was used for further docking studies.

Homology modelling and structure optimization of mutated hub-protein

Individual mutated models of selected five SNPs of α -Synuclein (A53T, A53E, E46K, H50Q, and G51D) were constructed by homology modelling using the Swiss Model, in template mode with PDB ID: 6CU8, selected as template. The modelled structures of mutated α -Synuclein were subjected to energy minimization and root mean square deviation (RMSD) was calculated using Chimera. A significant RMSD was observed between monomeric units of mutated α -Synuclein with respect to wild-type (WT) α -Synuclein, ranging from 0.108 to 0.118 (Table 4).

Table 4

RMSD matrix of structural alignment of monomeric forms of wild-type α -Synuclein and the selected SNPs – A53T (rs104893877), A53E (rs1553408288), E46K (rs104893875), H50Q (rs201106962) and G51D (rs431905511)

α -Synuclein (Wild/SNPs)	Wild	A53T	A53E	G51D	H50Q	E46K
Wild	-	0.110	0.108	0.118	0.112	0.115
A53T	-	-	0.009	0.041	0.007	0.014
A53E	-	-	-	0.042	0.008	0.022
G51D	-	-	-	-	0.041	0.060
H50Q	-	-	-	-	-	0.010
E46K	-	-	-	-	-	-

Protein-protein docking to study the effect of mutations on multimerization

Protein-protein docking studies were carried out successively, with dimer-monomer docking to form a trimer, followed by dimer-dimer and trimer-monomer docking to form a

tetramer and so on till decamerization, to evaluate the differential pattern of aggregations of WT and mutated forms of α -Synuclein proteins and to analyse the effect of SNPs or point-mutations on aggregation/self-assembly of α -Synuclein proteins.

The analyses of the docking studies (Tables 5a-c) revealed that for tetramerization, we had two possible combinations of trimer-monomer (III-I) and dimer-dimer (II-II). All the mutated and the WT structures showed better affinity to self-associate in the II-II combination except for the SNP E46K, which showed better results in the III-I combination (Table 5a). For the Pentamer, we had two combinations, III-II and IV-I. All the models showed better affinities in the IV-I combination. For Hexamer, a total of three combinations V-I, IV-II and III-III were evaluated for oligomerization. Except for the A53T, which showed lower energy in the IV-II combination, all others showed lower energies in the V-I combination hence, the better affinity than other studied combinations (Table 5a).

The heptamerization also had 3 possible combinations, V-II, IV-III and VI-I. The WT and SNPs- E46K and H50Q, had better affinities in VI-I pairing, while A53E and G51D had lower energies in the V-II

combination and A53T showed better affinity for IV-III combination (Table 5b). Four possible octamerisation combinations were investigated in our study: V-III, VI-II, VII-I and IV-IV. All the studied models of SNPs showed better affinity to self-associate in the IV-IV combination except for E46K, which had lower energy in the VII-I combination and showed a twisted morphology in the IV-IV pairing (Table 5b).

For nonamerization, again we had four combinations, V-IV, VI-III, VII-II and VI-III. WT, A53T, G51D, and H50Q had lower energies in V-IV combinations, while A53E and E46K showed better affinities in VII-II and VI-III combinations respectively (Table 5c). In the case of Decamerization, we had five possible combinations, VIII-II, V-V, VI-IV, VII-III and IX-I for evaluation. Except for the E46K, all other models gave better affinities in the VI-IV combination. However, E46K showed better affinity in the VII-III combination (Table 5c).

Table 5a

Binding energies of docked complexes of wild-type and mutated α -Synuclein proteins to obtain dimers, trimers, tetramers, pentamers and hexamers

α -Synuclein (Wild/SNPs)	Dimer	Trimer	Tetramer		Pentamer		Hexamer		
	I-I	II-I	III-I	II-II	IV-I	III-II	V-I	IV-II	III-III
WILD	-1284.44	-1006.67	-1123.81	-1220.84	-1135.17	-958.31	-1089.8	-911.22	-798.39
A53T	-1218.55	-1090.57	-1150.95	-1212.36	-1188.24	-1037.01	-1082.07	-1095.66	-980.28
A53E	-1200.88	-1178.59	-1013.32	-1122.8	-1079.33	-1045.54	-1064.39	-1036.24	-725.54
G51D	-1237.82	-1141.82	-1008.35	-1013.6	-1189.34	-951.67	-1041.29	-967.1	-798.57
H50Q	-1222.79	-1084.6	-1047.31	-1126.58	-1149.06	-1085.85	-1146.32	-1017.25	-947.39
E46K	-1224.09	1141.19	-1087.8	-980.81	-1049.75	-937.65	-1025.22	-980.32	-777.64

Table 5b

Binding energies of docked complexes of wild-type and mutated α -Synuclein proteins to obtain heptamers and octamers

α -Synuclein (Wild/SNPs)	Heptamer			Octamer			
	V-II	IV-III	VI-I	V-III	VI-II	VII-I	IV-IV
WILD	-902.98	-962.79	-984.96	-878.52	-835.63	-1124.55	-1141.46
A53T	-1107.35	-1118.09	-971.23	-988.88	-1230.1	-1177.15	-1275.41
A53E	-1112.47	-809.78	-990.73	-883.8	-970.95	-1084.05	-1338.22
G51D	-1053.03	-875.62	-1018.41	841.37	-833.75	-917.22	-1381.83
H50Q	-967.94	-1000.77	-1025.62	-975.61	-1027.87	-1127.71	-1184.2
E46K	-715.19	-833.17	-1169.64	-581.5	-1107.87	-1178.55	-861.48

Table 5

Binding energies of docked complexes of wild-type and mutated α -Synuclein proteins to obtain nonamers and decamers

α -Synuclein (Wild/SN Ps)	Nonamer				Decamer				
	V-IV	VI-III	VII-II	VIII-I	VIII-II	V-V	VI-IV	VII-III	IX-I
WILD	-1256.7	-808.33	-872.89	-1068.26	-820.1	-725.79	-1038.42	-819.38	-957.6
A53T	-1330.33	-986.19	-1165.09	-989.27	-992.5	-961.68	-1054.96	-878.75	-964.87
A53E	-971.6	-904.33	-1001.5	-921	-934.34	-794.51	-953.24	-834.33	-799.38
G51D	-920.69	-916.04	-822.07	-895.93	-700.82	-869.84	-899.17	-839.05	-843.84
H50Q	-1117.27	-885.2	-1077.63	-880.43	-1023.94	-880.34	-1096.42	-874.3	-942.14
E46K	-708.62	-1178.78	-1104.89	-1070.05	-488.55	-762.41	-833.23	-1199.71	-1071.51

Analysis of the effect of mutations on aggregation/self-assembly

Our study revealed altered binding energies (Table 6) and morphologies (Fig. 3a-f) of the mutated oligomeric structures in comparison to WT oligomeric structures of α -Synuclein. On self-assembly of A53T mutant, a lower binding energy (-1054.96 KJ/mol) was observed at the decamer stage i.e. oligomeric form, in comparison to WT α -Synuclein (-1038.4 KJ/mol), indicating high affinity of oligomerization of the former structure. A low affinity of self-assembly was observed for the A53E mutant, having higher binding energy

(-953.24 KJ/mol) on decamerization. The findings were observed to be in good concurrence with earlier reports [29, 30], which showed that the substitution of alanine with threonine at the 53 position in the A53T mutant formed a steric zipper in the core region of α -Synuclein oligomers, explaining the tendency of A53T mutant to aggregate at a higher rate compared to WT α -Synuclein while the substitution of Alanine with Glutamate at 53 position (A53E) has been reported to decrease the rate of aggregation/ self-assembly [29].




Fig. 3. Self-aggregation patterns of decameric forms of a) wild-type α -Synuclein protein [PDB: 6CU8] and single nucleotide polymorphic α -Synuclein proteins- b) A53E (rs1553408288); c) A53T (rs104893877); d) E46K (rs104893875); e) G51D (rs431905511) and f) H50Q (rs201106962).

Table 6

Binding energies of docked complexes of wild-type and mutated α -Synuclein proteins having maximum binding affinity

α -Synuclein (Wild/SNPs)	Dimer	Trimer	Tetramer	Pentamer	Hexamer	Heptamer	Octamer	Nonamer	Decamer
Wild	-1284.44	-1006.67	-1220.84	-1135.17	-1089.8	-984.96	-1141.46	-1256.7	-1038.42
A53T	-1218.55	-1090.57	-1212.36	-1188.24	-1095.66	-1107.35	-1275.41	-1330.33	-1054.96
A53E	-1200.88	-1178.59	-1122.8	-1079.33	-1064.39	-1112.47	-1338.22	-1001.5	-953.24
G51D	-1237.82	-1141.82	-1013.6	-1189.34	-1041.29	-1053.03	-1381.83	-920.69	-899.17
H50Q	1222.79	-1084.6	-1126.58	-1149.06	-1146.32	-1025.62	-1184.2	-1117.27	-1096.42
E46K	-1224.09	-1141.19	-1087.8	-1049.75	-1025.22	-1169.64	-1178.55	-1178.78	-1199.71

For the E46K mutation, lower binding energy (-1199.71 KJ/mol) was observed in comparison to WT (-1038.4 KJ/mol) and A53T (-1054.96 KJ/mol) mutant of α -Synuclein, along with a twisted morphology at the nonamer and decamer stages (Fig. 3d). This observation can be inferred from its high affinity of self-aggregation as compared to WT and A53T mutant of α -Synuclein concurrent to the previous studies [29, 30], which explained the formation of stabilizing salt bridge due to the close proximity of E46 and K80, causing enhanced electrostatic repulsion and increased propensity of oligomerization.

The present docking study of H50Q mutation of α -Synuclein for self-aggregation revealed a lower binding energy (-1096.42 KJ/mol) as compared to WT α -Synuclein (-1038.4 KJ/mol). The observation was also in accordance with the earlier reports [26, 30], which explained that the substitution of His with Gln eliminated the imidazole's positive charge, thereby, preventing the formation of a salt bridge with adjacent filament. Just like E46K, in the case of H50Q also, there is a destabilization of the interface between the protofibril dimers, creating a potential shift in the equilibrium favoring self-aggregation in α -Synuclein.

For the G51D mutant, a significant rise in the binding energy (-899.17 KJ/mol) was observed in higher oligomeric units like nonamer and decamer, in addition to the disrupted morphology (Fig. 3e). The reduced binding affinity of the G51D mutant in later stages of the oligomerization may be inferred as its decreased rate of aggregation, in concurrence with the previous studies [26, 30], which elucidated that the additional steric bulk was responsible for the loss of flexibility and hydrophobicity of G51D matured α -Synuclein, causing the decreased rate of self-assembly.

Molecular dynamics simulation study

The stability of the decameric form of WT α -Synuclein was studied by molecular dynamics simulation (MDS) and observed to be stable throughout the period of 100 ns. The root mean square deviation (RMSD) value was found to increase gradually from a time scale of 0.1ns to 36.7ns, and after that, the RMSD value is observed to be stable within the 3Å (0.30 nm) limit, varying within the lowest of 0.61 at 36.8ns and a highest of 0.85 at 69 ns up to 100ns (Fig. 4a). Thus, validating the docked complex of the WT α -Synuclein.




Fig. 4. Molecular dynamics simulation study of the decameric form of wild-type α -Synuclein protein a) Root mean square deviation (RMSD) b) Root mean square fluctuation (RMSF) c) Solvent accessible surface area (SASA) d) Radius of gyration (Rg)

The root mean square fluctuation (RMSF) was calculated (Fig. 4b), and major peaks were observed for the tails (N and C-terminal) and minor peaks were observed for the loop region of each monomeric unit (43-83 amino acids). The beta-sheet domain was observed to be stable for each monomeric unit in the decameric conformation, indicating a stable docked complex of WT α -Synuclein.

The solvent-accessible surface area (SASA) was observed to be constantly varying between 200-250nm². This small change in SASA explains the minor changes in the structure of the docked complex along the simulation and hence reflects towards stability of the docked decameric complex of WT α -Synuclein (Fig. 4c).

The radius of gyration (Rg) for x (Rg_x), y (Rg_y) and z-axis (Rg_z) were observed to be varying between 1.67 nm and 2.14 nm, whereas the total radius of gyration (Rg_t) was found to be constantly stabilizing around 2.3 nm, thus hinting further towards the stability of studied structure of decameric docked complex of WT α -Synuclein (Fig. 4d).

Conclusion. The present *in-silico* work was undertaken to identify the main

therapeutic target protein responsible for PD and the effect of mutations on its pathophysiology. The study revealed α -Synuclein as the main target protein, which is a highly dynamic and disordered protein, existing in multiple polymorphs. Therefore, the common kernel structure of the α -Synuclein was selected to study different oligomerization patterns.

The protein-protein docking study for self-aggregation of five α -Synuclein mutations (A53T, A53E, E46K, G51D and H50Q) revealed that there was a significant change in the binding energies of SNPs in comparison to WT α -Synuclein on oligomerization. 3 SNPs – A53T, E46K and H50Q demonstrated lower binding energies in the decamer stage of oligomers, indicating higher affinities and higher rates of self-aggregation, while 2 SNPs – A53E and G51D displayed higher binding energies in the decameric form, inferring lower affinities and lower rates of aggregation in comparison to WT α -synuclein. G51D and E46K mutated oligomeric structures of α -Synuclein showed twisted morphologies, which may cause a decrease or increase in the rates of aggregation depending upon the

structural changes in the active site of α -Synuclein protein. The decameric form of WT α -Synuclein was observed to be stable throughout the molecular dynamics simulation study of 100ns thus reflecting towards its stability. The present study provides a good platform for further investigation to establish α -Synuclein decameric form as a major target protein for PD therapeutic design and development.

Financial support

No financial support has been provided for this work.

Conflict of interests

The authors have no conflict of interest to declare.

References

1. Kalia LV, Lang AE. Parkinson's disease. *The Lancet*. 2015;386(9996):896-912. DOI: [https://doi.org/10.1016/S0140-6736\(14\)61393-3](https://doi.org/10.1016/S0140-6736(14)61393-3)
2. Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. *Movement Disorders*. 2008;23(Suppl 3):S548-S559. DOI: <https://doi.org/10.1002/mds.22062>
3. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. *Trends in Neurosciences*. 1989;12(10):366-375. DOI: [https://doi.org/10.1016/0166-2236\(89\)90074-x](https://doi.org/10.1016/0166-2236(89)90074-x)
4. DeLong MR. Primate models of movement disorders of basal ganglia origin. *Trends in Neurosciences*. 1990;13(7):281-285. DOI: [https://doi.org/10.1016/0166-2236\(90\)90110-v](https://doi.org/10.1016/0166-2236(90)90110-v)
5. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science*. 1997;276(5321):2045-2047. DOI: <https://doi.org/10.1126/science.276.5321.2045>
6. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. *Nature*. 1997;388(6645):839-840. DOI: <https://doi.org/10.1038/42166>
7. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature*. 1998;392(6676):605-608. DOI: <https://doi.org/10.1038/33416>
8. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science*. 2003;299(5604):256-259. DOI: <https://doi.org/10.1126/science.1077209>
9. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science*. 2004;304(5674):1158-1160. DOI: <https://doi.org/10.1126/science.1096284>
10. Paisán-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron*. 2004;44(4):595-600. DOI: <https://doi.org/10.1016/j.neuron.2004.10.023>
11. Kanehisa M, Goto S, Furumichi M, et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. *Nucleic Acids Research*. 2010;38:D355-D360. DOI: <https://doi.org/10.1093/nar/gkp896>
12. Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Research*. 2023;51(D1):D638-D646. DOI: <https://doi.org/10.1093/nar/gkac1000>
13. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Research*. 2003;13(11):2498-2504. DOI: <https://doi.org/10.1101/gr.1239303>
14. Chin CH, Chen SH, Wu HH, et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Systems Biology*. 2014;8:S11. DOI: <https://doi.org/10.1186/1752-0509-8-S4-S11>
15. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. *Nucleic Acids Research*. 2000;28(1):235-242. DOI: <https://doi.org/10.1093/nar/28.1.235>
16. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. *Journal of Computational Chemistry*. 2004;25(13):1605-1612. DOI: <https://doi.org/10.1002/jcc.20084>
17. Schwede T, Kopp J, Guex N, et al. SWISS-MODEL: An automated protein homology-modeling server. *Nucleic Acids Research*. 2003;31(13):3381-3385. DOI: <https://doi.org/10.1093/nar/gkg520>
18. Macindoe G, Mavridis L, Venkatraman V, et al. HexServer: an FFT-based protein docking

server powered by graphics processors. *Nucleic Acids Research*. 2010;38:W445-W449. DOI: <https://doi.org/10.1093/nar/gkq311>

19. Berendsen HJC, van der Spoel D, van Drunen R. GROMACS: A message-passing parallel molecular dynamics implementation. *Computer Physics Communications*. 1995;91(1-3):43-56. DOI: [https://doi.org/10.1016/0010-4655\(95\)00042-E](https://doi.org/10.1016/0010-4655(95)00042-E)

20. Huang J, Rauscher S, Nawrocki G, et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. *Nature Methods*. 2017;14(1):71-73. DOI: <https://doi.org/10.1038/nmeth.4067>

21. Stephens AD, Zacharopoulou M, Moons R, et al. Extent of N-terminus exposure of monomeric alpha-synuclein determines its aggregation propensity. *Nature Communications*. 2020;11(1):2820. DOI: <https://doi.org/10.1038/s41467-020-16564-3>

22. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. *Science*. 1996;274(5290):1197-1199. DOI: <https://doi.org/10.1126/science.274.5290.1197>

23. Engelender S. Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease. *Autophagy*. 2008;4(3):372-374. DOI: <https://doi.org/10.4161/auto.5604>

24. Martikainen MH, Päivärinta M, Hietala M, et al. Clinical and imaging findings in Parkinson disease associated with the A53E SNCA mutation. *Neurology: Genetics*. 2015;1(4):e27. DOI: <https://doi.org/10.1212/NXG.0000000000000027>

25. Zarranz JJ, Alegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. *Annals of Neurology*. 2004;55(2):164-173. DOI: <https://doi.org/10.1002/ana.10795>

26. Rutherford NJ, Moore BD, Golde TE, et al. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α -synuclein. *Journal of Neurochemistry*. 2014;131(6):859-867. DOI: <https://doi.org/10.1111/jnc.12806>

27. Stephens AD, Zacharopoulou M, Schierle GSK. The Cellular Environment Affects Monomeric α -Synuclein Structure. *Trends in Biochemical Sciences*. 2019;44(5):453-466. DOI: <https://doi.org/10.1016/j.tibs.2018.11.005>

28. Li B, Ge P, Murray KA, et al. Cryo-EM of full-length α -synuclein reveals fibril polymorphs

with a common structural kernel. *Nature Communications*. 2018;9(1):3609. DOI: <https://doi.org/10.1038/s41467-018-05971-2>

29. Meade RM, Fairlie DP, Mason JM. Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles. *Molecular Neurodegeneration*. 2019;14(1):29. DOI: <https://doi.org/10.1186/s13024-019-0329-1>

30. Choi W, Zibae S, Jakes R, et al. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. *FEBS Letters*. 2004;576(3):363-368. DOI: <https://doi.org/10.1016/j.febslet.2004.09.038>

Received 20 February 2024

Revised 20 June 2024

Accepted 22 August 2024

Information about the authors

Annu Grewal, Researcher at the Toxicology and Computational Biology Group, Centre for Bioinformatics, Maharshi Dayanand University, Rohtak, India, E-mail: agrewal113@gmail.com, ORCID: <https://orcid.org/0000-0002-2935-4908>.

Riddhi Sharma, Researcher at the Toxicology and Computational Biology Group, Centre for Bioinformatics, Maharshi Dayanand University, Rohtak, India, E-mail: riddhi23.sharma@gmail.com, ORCID: <https://orcid.org/0009-0008-4461-0376>.

Deepak Sheokand, Researcher at the Toxicology and Computational Biology Group, Centre for Bioinformatics, Maharshi Dayanand University, Rohtak, India, E-mail: dpk.sheo@gmail.com, ORCID: <https://orcid.org/0000-0002-4647-8152>.

Pawan Kumar, Researcher at the Toxicology and Computational Biology Group, Centre for Bioinformatics, Maharshi Dayanand University, Rohtak, India, E-mail: patriotpawan@gmail.com, ORCID: <https://orcid.org/0000-0002-5765-0042>.

Vandana Saini, Researcher at the Toxicology and Computational Biology Group, Centre for Bioinformatics, Maharshi Dayanand University, Rohtak, India, E-mail: vandanas64@gmail.com, ORCID: <https://orcid.org/0000-0003-2734-0120>.

Ajit Kumar, Researcher at the Toxicology and Computational Biology Group, Centre for Bioinformatics, Maharshi Dayanand University, Rohtak, India, E-mail: akumar.cbt.mdu@gmail.com, ORCID: <https://orcid.org/0000-0001-7136-7182>.